BD14

BD14 is a preclinical-stage multibody drug conjugate (MDC) being developed by Biolojic Design for the treatment of oncology. The drug is developed using Biolojic Design's proprietary multibody platform, which utilizes computational design to create antibodies that can switch between different conformations or bind multiple targets conditionally. As an MDC, BD14 is designed to target specific tumor-associated antigens and deliver a cytotoxic payload directly to cancer cells, aiming to improve the therapeutic index compared to traditional antibody-drug conjugates. While the specific molecular targets and payload for BD14 have not been publicly disclosed, the program represents the company's expansion of its multibody technology into the conjugate space for cancer therapy.